Metagenomi Therapeutics MGX Income Statement (2023-2026)

NASDAQ MGX
$1.15 -0.01 (-0.86%)
At close: Sep 9, 2026 · 4:00 PM EDT
Reported Financials

Metagenomi Therapeutics Quarterly Income Statement

Periods 14 quarters
Latest Jun 2026

Metagenomi Therapeutics reported net income of -$27.56M for the quarter ended Jun 2026. This income statement covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.) 3.40M3.40M3.40M3.40M21.14M37.46M37.43M37.42M37.38M37.53M37.55M37.62M37.65M37.78M
Revenue & cost
Revenue 8.66M11.34M12.36M12.40M11.16M20.01M11.51M9.61M4.13M8.51M8.66M3.91M1.25M
Operating items
Research & DevelopmentR&D 20.13M22.68M26.84M24.75M31.44M28.32M26.26M23.16M25.14M22.51M25.28M21.50M19.30M22.51M
Selling, General & AdministrativeSG&A 6.46M6.62M7.92M7.84M8.75M8.55M7.64M7.07M6.80M6.99M6.21M6.78M6.54M6.00M
Operating ExpensesOpex 26.59M29.30M34.76M32.59M40.19M36.87M33.90M30.24M31.95M29.50M31.50M28.28M25.84M28.52M
Operating IncomeOp. Inc -17.94M-17.96M-22.39M-20.20M-29.03M-16.86M-22.38M-20.62M-27.82M-20.99M-22.84M-24.37M-24.59M-28.77M
EBIT -17.94M-17.96M-22.39M-20.20M-29.03M-16.86M-22.38M-20.62M-27.82M-20.99M-22.84M-24.37M-24.59M-28.77M
Non-operating items
Interest & Investment IncomeInt & Inv Inc 4.00M3.97M3.87M3.63M3.93M3.98M3.62M3.20M2.89M2.48M2.21M1.88M1.54M1.26M
Other Non Operating IncomeOther Non Op Inc. -0.00M0.02M-0.09M-0.00M-0.05M-0.05M-0.06M-0.05M-0.01M-0.07M-0.00M-0.01M-0.00M0.04M
Non Operating IncomeNon Op. Inc. 4.00M6.85M3.78M3.63M3.88M3.92M1.50M-3.98M2.88M1.12M2.21M1.87M1.54M1.29M
Net income details
EBT -13.94M-11.11M-18.61M-16.57M-25.15M-12.94M-20.88M-24.61M-24.94M-19.86M-20.63M-22.49M-23.05M-27.48M
Tax ProvisionsTaxes -2.20M1.90M1.21M2.73M-2.20M-2.11M-1.21M0.10M0.04M-0.23M-18.37M0.01M
Profit After TaxPAT -16.13M-13.01M-19.82M-19.21M-25.15M-10.74M-18.77M-23.40M-25.04M-20.16M-20.39M-22.64M-23.06M-27.56M
Income from Continuing OperationsIncome (Continuing) -11.74M-13.01M-19.82M-19.29M-25.15M-10.74M-18.77M-23.40M-25.04M-19.91M-20.39M-4.12M-23.06M-27.48M
Consolidated Net IncomeConsol Net Inc. -11.74M-13.01M-19.82M-19.29M-25.15M-10.74M-18.77M-23.40M-25.04M-19.91M-20.39M-4.12M-23.06M-27.48M
Income towards Parent CompanyParent Net Inc -11.74M-13.01M-19.82M-19.29M-25.15M-10.74M-18.77M-23.40M-25.04M-19.91M-20.39M-4.12M-23.06M-27.48M
Net Income towards Common StockholdersNet Income -16.13M-13.01M-19.82M-19.29M-25.15M-10.74M-18.77M-23.40M-25.04M-19.91M-20.39M-22.53M-23.06M-27.48M
Additional items
EPS (Basic) -4.74-3.82-5.82-5.67-1.19-0.29-0.51-0.71-0.68-0.54-0.55-0.60-0.61-0.73
EPS (Diluted) -4.74-3.82-5.82-5.67-1.19-0.29-0.51-0.71-0.68-0.54-0.55-0.60-0.61-0.73
Shares Outstanding 3.40M3.40M3.40M3.40M21.14M36.63M36.77M33.03M37.02M37.16M37.35M37.25M37.58M37.66M
Shares Outstanding (Diluted)Shares Outstanding (Dil.) 3.40M3.40M3.40M3.40M21.14M36.63M36.77M33.03M37.02M37.16M37.35M37.25M37.58M37.66M
EBITDA -17.94M-17.96M-22.39M-20.20M-29.03M-16.86M-22.38M-20.62M-27.82M-20.99M-22.84M-24.37M-24.59M-28.77M
Tax Rate 15.76-17.08-6.48-16.4517.0010.094.91-0.39-0.221.1381.68-0.04